Clinical Pharmacokinetics of Capecitabine
Top Cited Papers
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (2), 85-104
- https://doi.org/10.2165/00003088-200140020-00002
Abstract
Capecitabine is a novel oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety fluorouracil (5-fluorouracil; 5-FU) in target tumour tissue through a series of 3...Keywords
This publication has 54 references indexed in Scilit:
- Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?European Journal Of Cancer, 2000
- A Randomized Study of Bolus Fluorouracil Plus Folinic Acid Versus 21-Day Fluorouracil Infusion Alone or in Association with Cyclophosphamide and Mitomycin C in Advanced Colorectal CarcinomaAmerican Journal of Clinical Oncology, 1995
- Severe Fluorouracil Toxicity in a Patient With Dihydropyrimidine Dehydrogenase DeficiencyJNCI Journal of the National Cancer Institute, 1993
- Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasmaCancer Chemotherapy and Pharmacology, 1993
- The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeuticsPharmacology & Therapeutics, 1991
- Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of TaxolJNCI Journal of the National Cancer Institute, 1991
- Drug interactions with quinolonesJournal of Antimicrobial Chemotherapy, 1990
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989
- Cellular pharmcology of fluorinated pyrimidines in vivo in manInvestigational New Drugs, 1989
- Fluorouracil Therapy in Patients With Carcinoma of the Large BowelClinical Pharmacokinetics, 1978